PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2024/30 - Esteve / Perrigo
Acquiring
Esteve Healthcare S.L.
Description
An international specialty pharmaceutical group, it is active across the entire pharmaceutical value chain, from pre-clinical research to the production and marketing of finished pharmaceutical forms. Esteve has two business divisions: (i) the therapeutic division and (ii) the contract development division and production organization of active pharmaceutical ingredients, intermediates and advanced technologies. In Portugal, Esteve is present through Esteve Pharmaceuticals – Laboratório Farmacêutico, Lda..
Acquired
Hra Pharma Iberia S.L, Sucursal em Portugal
Description
Perrigo is present in Portugal through HRA Pharma Iberia S.L, comprising three medicines intended for the treatment of orphan endocrine and oncological diseases: Lysodren (medicine indicated to treat symptoms of advanced adrenocortical carcinoma), Metopirone and Ketoconazole (both used to diagnose and treat Cushing's syndrome).
Sector
Activity (NACE)
Applicable legislation
Notification thresholds
Type of merger
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description

The merger operation consists of the acquisition by Esteve Healtchcare S.L. ("Esteve") of exclusive control of the medicines business for the treatment of rare diseases from Perrigo Company plc ("Perrigo").
Timeline
2024-06-12
The AdC issued a non-opposition decision to the merger 30/2024 - Esteve / PerrigoBelAudição.
2024-05-21
Esteve Healtchcare notifies the acquisition of exclusive control over HRA Pharma Iberia.
Click here to see your activities